Umut Kocabaş, Işıl Ergin, Veysel Yavuz, Selda Murat, Ibrahim Özdemir, Ömer Genç, Cihan Altın, Haşim Tüner, Bengisu Keskin Meriç, Ali Çoner, Elif İlkay Yüce, Bedrettin Boyraz, Onur Aslan, Ahmet Dal, Taner Şen, Ersin İbişoğlu, Aslan Erdoğan, Mehmet Özgeyik, Mevlüt Demir, Ziya Gökalp Bilgel, Büşra Güvendi Şengör, Örsan Deniz Urgun, Mustafa Doğduş, Deniz Dilan Naki Tekin, Sinem Çakal, Sercan Çayırlı, Arda Güler, Dilay Karabulut, Onur Dalgıç, Osman Uzman, Bektaş Murat, Şeyda Şahin, Umut Karabulut, Tarık Kıvrak, Muharrem Said Coşgun, Ferhat Özyurtlu, Mehmet Kaplan, Emre Özçalık
{"title":"Real-World Evaluation of Anticoagulant Treatment Patterns in Patients with Atrial Fibrillation: Data from Multicenter ROTA Study.","authors":"Umut Kocabaş, Işıl Ergin, Veysel Yavuz, Selda Murat, Ibrahim Özdemir, Ömer Genç, Cihan Altın, Haşim Tüner, Bengisu Keskin Meriç, Ali Çoner, Elif İlkay Yüce, Bedrettin Boyraz, Onur Aslan, Ahmet Dal, Taner Şen, Ersin İbişoğlu, Aslan Erdoğan, Mehmet Özgeyik, Mevlüt Demir, Ziya Gökalp Bilgel, Büşra Güvendi Şengör, Örsan Deniz Urgun, Mustafa Doğduş, Deniz Dilan Naki Tekin, Sinem Çakal, Sercan Çayırlı, Arda Güler, Dilay Karabulut, Onur Dalgıç, Osman Uzman, Bektaş Murat, Şeyda Şahin, Umut Karabulut, Tarık Kıvrak, Muharrem Said Coşgun, Ferhat Özyurtlu, Mehmet Kaplan, Emre Özçalık","doi":"10.5543/tkda.2022.98455","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Oral anticoagulant therapy is the cornerstone of atrial fibrillation management to prevent stroke and systemic embolism. However, there is limited real-world information regarding stroke and systemic embolism prevention strategies in patients with atrial fibrillation. The aim of the ROTA study is to obtain the real-world data of anticoagulant treatment patterns in patients with atrial fibrillation.</p><p><strong>Methods: </strong>The ROTA study is a prospective, multicenter, and observational study that included 2597 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January 2021 and May 2021.</p><p><strong>Results: </strong>The median age of the study population was 72 years (range: 22-98 years) and 57.4% were female. The median CHA2DS2-VASc and HAS-BLED scores were 4 (range: 0-9) and 1 (range: 0-6), respectively. Vitamin K antagonists and direct oral anticoagulants were used in 15.9% and 79.4% of patients, respectively. The mean time in therapeutic range was 52.9% for patients receiving vitamin K antagonists, and 76% of those patients had an inadequate time in therapeutic range with <70%. The most common prescribed direct oral anticoagulants were rivaroxaban (38.1%), apixaban (25.5%), and edoxaban (11.2%). The rate of overuse of vitamin K antagonists and direct oral anticoagulants was high (76.1%) in patients with low stroke risk, and more than one-fourth of patients on direct oral anticoagulant therapy were receiving a reduced dose of direct oral anticoagulants. Among patients who were on direct oral anticoagulant treatment, patients with apixaban treatment were older, had higher CHA2DS2-VASc and HAS-BLED scores, and had lower creatinine clearance than the patients receiving other direct oral anticoagulants.</p><p><strong>Conclusions: </strong>The ROTA study provides important real-world information about anticoagulant treatment patterns in patients with atrial fibrillation.time in therapeutic range with <70%.</p>","PeriodicalId":46993,"journal":{"name":"Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5543/tkda.2022.98455","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Oral anticoagulant therapy is the cornerstone of atrial fibrillation management to prevent stroke and systemic embolism. However, there is limited real-world information regarding stroke and systemic embolism prevention strategies in patients with atrial fibrillation. The aim of the ROTA study is to obtain the real-world data of anticoagulant treatment patterns in patients with atrial fibrillation.
Methods: The ROTA study is a prospective, multicenter, and observational study that included 2597 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January 2021 and May 2021.
Results: The median age of the study population was 72 years (range: 22-98 years) and 57.4% were female. The median CHA2DS2-VASc and HAS-BLED scores were 4 (range: 0-9) and 1 (range: 0-6), respectively. Vitamin K antagonists and direct oral anticoagulants were used in 15.9% and 79.4% of patients, respectively. The mean time in therapeutic range was 52.9% for patients receiving vitamin K antagonists, and 76% of those patients had an inadequate time in therapeutic range with <70%. The most common prescribed direct oral anticoagulants were rivaroxaban (38.1%), apixaban (25.5%), and edoxaban (11.2%). The rate of overuse of vitamin K antagonists and direct oral anticoagulants was high (76.1%) in patients with low stroke risk, and more than one-fourth of patients on direct oral anticoagulant therapy were receiving a reduced dose of direct oral anticoagulants. Among patients who were on direct oral anticoagulant treatment, patients with apixaban treatment were older, had higher CHA2DS2-VASc and HAS-BLED scores, and had lower creatinine clearance than the patients receiving other direct oral anticoagulants.
Conclusions: The ROTA study provides important real-world information about anticoagulant treatment patterns in patients with atrial fibrillation.time in therapeutic range with <70%.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
